ATE214161T1 - Verfahren zur diagnose adenokarzinom oder benigne pathologie der vorsteherdrüse - Google Patents

Verfahren zur diagnose adenokarzinom oder benigne pathologie der vorsteherdrüse

Info

Publication number
ATE214161T1
ATE214161T1 AT99929407T AT99929407T ATE214161T1 AT E214161 T1 ATE214161 T1 AT E214161T1 AT 99929407 T AT99929407 T AT 99929407T AT 99929407 T AT99929407 T AT 99929407T AT E214161 T1 ATE214161 T1 AT E214161T1
Authority
AT
Austria
Prior art keywords
cleaved
psa
free psa
diagnosing
free
Prior art date
Application number
AT99929407T
Other languages
English (en)
Inventor
Jean-Philippe Charrier
Carole Tournel
Michel Jolivet
Original Assignee
Bio Merieux
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bio Merieux filed Critical Bio Merieux
Application granted granted Critical
Publication of ATE214161T1 publication Critical patent/ATE214161T1/de

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5758—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites
    • G01N33/57585—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites involving compounds identifiable in body fluids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57555—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the prostate

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
AT99929407T 1998-07-03 1999-07-05 Verfahren zur diagnose adenokarzinom oder benigne pathologie der vorsteherdrüse ATE214161T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR9808702A FR2780791B1 (fr) 1998-07-03 1998-07-03 Methode de depistage ou de diagnostic d'un adenocarcinome ou d'une pathologie benigne de la prostate et procede de mise en oeuvre
PCT/FR1999/001622 WO2000002052A1 (fr) 1998-07-03 1999-07-05 Methode de diagnostic d'un adenocarcinome ou d'une pathologie benigne de la prostate

Publications (1)

Publication Number Publication Date
ATE214161T1 true ATE214161T1 (de) 2002-03-15

Family

ID=9528375

Family Applications (1)

Application Number Title Priority Date Filing Date
AT99929407T ATE214161T1 (de) 1998-07-03 1999-07-05 Verfahren zur diagnose adenokarzinom oder benigne pathologie der vorsteherdrüse

Country Status (9)

Country Link
US (1) US6929918B1 (de)
EP (1) EP1095276B1 (de)
JP (1) JP4364437B2 (de)
AT (1) ATE214161T1 (de)
AU (1) AU4623599A (de)
CA (1) CA2336174C (de)
DE (1) DE69900998T2 (de)
FR (1) FR2780791B1 (de)
WO (1) WO2000002052A1 (de)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2807438B1 (fr) * 2000-04-10 2004-09-17 Bio Merieux Nouveaux anticorps reconnaissant specifiquement le psa libre inactif, et leurs applications
ES2269440T3 (es) * 2000-05-24 2007-04-01 F. Hoffmann-La Roche Ag Anticuerpos contra formas especiales de propsa y su utilizacion en inmunoensayos.
FR2810114B1 (fr) * 2000-06-13 2002-08-23 Bio Merieux Methode, procede, test immunologique et kit de diagnostic d'un adenocarcinome de la prostate ou d'une hypertrophie benigne de la prostate
ATE287430T1 (de) 2000-09-06 2005-02-15 Evotec Ag Oxazinderivate
JP4681175B2 (ja) * 2001-09-28 2011-05-11 三菱化学メディエンス株式会社 播種性血管内凝固症候群及びその発症前段階を検出する方法
GB0217831D0 (en) * 2002-08-01 2002-09-11 Sweetapple Matthew J Risqué method and device
CN1926433A (zh) * 2004-03-03 2007-03-07 拜奥默里克斯公司 用于检测psa的可活化游离形式的方法及其用于诊断前列腺的良性病理学和前列腺的腺癌的用途
US20080125582A1 (en) * 2006-10-13 2008-05-29 Bio-Rad Laboratories, Inc. Methods and compositions for stabilizing prostate specific antigen
CN102520161A (zh) * 2012-01-05 2012-06-27 中南大学 一种用于spr双通道法检测前列腺特异性抗原的生物传感芯片、试剂盒，检测方法
CN108108590A (zh) * 2012-03-05 2018-06-01 阿克蒂克合伙公司 分析系统和方法
WO2013146997A1 (ja) * 2012-03-30 2013-10-03 国立大学法人京都大学 前立腺がん検査用尿中バイオマーカー
MX392384B (es) 2014-03-28 2025-03-24 Opko Diagnostics Llc Composiciones y metodos relacionados con el diagnostico de cancer de prostata.
US12326453B2 (en) 2014-03-28 2025-06-10 Opko Diagnostics, Llc Compositions and methods for active surveillance of prostate cancer
EP3253800B1 (de) 2015-03-27 2021-03-03 Opko Diagnostics, LLC Prostata-antigenstandards und verwendungen davon

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5710007A (en) * 1995-09-29 1998-01-20 Luderer; Albert A. Methods for diagnosing prostatic adenocarcinoma

Also Published As

Publication number Publication date
EP1095276B1 (de) 2002-03-06
WO2000002052A1 (fr) 2000-01-13
FR2780791B1 (fr) 2000-09-01
EP1095276A1 (de) 2001-05-02
CA2336174A1 (fr) 2000-01-13
DE69900998T2 (de) 2002-11-07
JP2002519701A (ja) 2002-07-02
AU4623599A (en) 2000-01-24
US6929918B1 (en) 2005-08-16
DE69900998D1 (de) 2002-04-11
FR2780791A1 (fr) 2000-01-07
JP4364437B2 (ja) 2009-11-18
CA2336174C (fr) 2012-05-15

Similar Documents

Publication Publication Date Title
DE69623264D1 (de) Verfahren zur diagnose gutartiger prostataerkrankungen
DE69900998D1 (de) Verfahren zur diagnose adenokarzinom oder benigne pathologie der vorsteherdrüse
Riehmann et al. Analysis of variation in prostate-specific antigen values
Oesterling Prostate specific antigen: a critical assessment of the most useful tumor marker for adenocarcinoma of the prostate
ATE198513T1 (de) Ptpalpha-bestimmung in der tumordiagnose und - prognose
AU4694499A (en) Trace level detection of analytes using artificial olfactometry
Breul et al. Prostate-specific antigen in urine
Wajsman et al. Clinical significance of serum alkaline phosphatase isoenzyme levels in advanced prostatic carcinoma
HUP9701717A2 (hu) Eljárás cPSA-meghatározására
Tavassoli et al. Elevation of serum acid phosphatase in cancers with bone metastasis
ATE350662T1 (de) Markerproteine für prostatakrebs
DE69704031D1 (de) Test zur diagnose eines erhöhten brustkrebs-risikos
Larsen et al. Can stage A1 tumor extent be predicted by transurethral resection tumor volume, per cent or grade? A study of 64 stage A1 radical prostatectomies with comparison to prostates removed for stages A2 and B disease
ATE126599T1 (de) Verfahren zur bestimmung von anti-rns- antikörpern.
SE9401883L (sv) Sätt vid diagnosticering av födoämnesintolerans/allergi samt instrument för diagnostiseringen
ATE404676T1 (de) Prostat-spezifisches-antigenformen und verfahren zu ihrer bestimmung
Jacobsen et al. Stability of serum prostate-specific antigen determination across laboratory, assay, and storage time
Wymenga et al. Pretreatment levels of urinary deoxypyridinoline as a potential marker in patients with prostate cancer with or without bone metastasis
Silver et al. Prediction of malignant melanoma recurrence by serum N‐acetylneuraminic acid
Green et al. Thickness is not an accurate gauge of prognosis of primary cutaneous melanoma
ATE135468T1 (de) Vorprüfung von prostatakrebs durch serum prostatischen spezifischen antigen
FR2810114B1 (fr) Methode, procede, test immunologique et kit de diagnostic d'un adenocarcinome de la prostate ou d'une hypertrophie benigne de la prostate
ATE130100T1 (de) Verfahren zur immunologischen erkennung maligner tumore und kit zur durchführung dieses verfahrens.
ATE485515T1 (de) Verfahren zur diagnose einer person mit multipler sklerose
ATE283479T1 (de) Verfahren und testsatz zur bestimmung der analytkonzentration im blut

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties